Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis.

Trial Profile

Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Mometasone (Primary) ; Oxymetazoline (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 26 Mar 2010 Results were presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 02 Mar 2010 QOL results presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 02 Mar 2010 Results were presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top